Truscreen GroupASX:TRU OCF Yield % is -14.05 as of Jun. 30, 2026. The stock has 6 warning signs investors should review. Among 851 Medical Devices & Instruments companies, Truscreen Group ranks worse than 80.85% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Truscreen Group's OCF Yield % or its related term are showing as below:
ASX:TRU'
s OCF Yield % Range Over the Past 10 Years
Min: -31.71 Med: -11.94 Max: -1.67
Current: -14.05
During the past 12 years, the highest OCF Yield % of Truscreen Group was -1.67%. The lowest was -31.71%. And the median was -11.94%.
ASX:TRU's OCF Yield % is ranked worse than 80.85% of 851
companies
in the Medical Devices & Instruments industry
Industry Median: 1.79
vs ASX:TRU: -14.05
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Truscreen Group OCF Yield % Related Terms
Truscreen Group OCF Yield % Historical Data
* Premium members only.
The historical data trend for Truscreen Group's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Truscreen Group's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Truscreen Group OCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Truscreen Group's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Truscreen Group's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Truscreen Group (ASX:TRU) has a OCF Yield % of -14.05 as of Jun. 30, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Truscreen Group and its competitors. According to the industry distribution chart, Truscreen Group ranks #688 out of 851 companies in the Medical Devices & Instruments industry, placing it in the top 80.8%.
Is Truscreen Group's OCF Yield % too high?
Truscreen Group's current OCF Yield % is -14.05. Based on the distribution chart, Truscreen Group ranks #688 out of 851 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Truscreen Group's OCF Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Truscreen Group ranks #688 out of 851 companies for OCF Yield %. This places Truscreen Group in the lower half of its industry. The industry median OCF Yield % is 1.79. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Devices & Instruments company?
The median OCF Yield % among Medical Devices & Instruments companies is 1.79, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Truscreen Group and its competitors. For the Medical Devices & Instruments industry, the median OCF Yield % is 1.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Truscreen Group's current OCF Yield % is -14.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Truscreen Group stock overvalued right now?
Based on GuruFocus' analysis, Truscreen Group (ASX:TRU) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.01 — trading 30% below its estimated fair value. The current OCF Yield % is -14.05. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Truscreen Group (ASX:TRU), the current OCF Yield % is -14.05 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Truscreen Group Ltd is a medical device company. The company manufactures and distributes the Truscreen Cervical Cancer screening device, which comprises a medical device and process designed to detect the presence in real-time of precancerous and cancerous tissue on the cervix. The product utilizes technology to detect the pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurements of cervical tissue. Geographically, the company operates its business in New Zealand, Mexico, China, Russia, Zimbabwe, Vietnam, and other countries. Maximum revenue is generated from China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:TRU has been successfully added to your 